Temporal trends in craniopharyngioma management and long-term endocrine outcomes: A multicentre cross-sectional study

Ziad Hussein1,2 | Nigel Glynn3 | Niamh Martin4 | Akram Alkrekshi5 | Nigel Mendoza6 | Ramesh Nair6 | Katherine McCullough7 | Hani J. Marcus8 | Neil Dorward8 | Joan Grieve8 | Naomi Fersht9 | Edward Dyson10 | Pierre-Marc Bouloux11 | Maralyn Druce3,12 | Stephanie E. Baldeweg1,2

1Department of Endocrinology, University College London Hospital, London, UK
2Department of Medicine, University College London, London, UK
3Department of Endocrinology, St Bartholomew’s Hospital, Bart’s Health NHS Trust, London, UK
4Division of Diabetes, Endocrinology and Metabolism, Imperial College London, UK
5Internal Medicine, The Metro Health System Campus of Case Western Reserve University, Cleveland, USA
6Department of Neurosurgery, Imperial College Healthcare NHS Trust, London, UK
7Department of Diabetes and Endocrinology, Royal Surrey County Hospital, Guildford, UK
8Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK
9Department of Oncology, University College London Hospital, London, UK
10Department of Neurosurgery, Great Ormond Street Hospital NHS Foundation Trust, London, UK
11Centre for Neuroendocrinology, Royal Free Campus, University College London, London, UK
12Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Correspondence
Ziad Hussein, Department of Endocrinology, University College London Hospital, London, UK.
Email: Ziad.hussein1@nhs.net

Abstract

Background: The optimal management of craniopharyngiomas remains controversial. Objectives: To examine temporal trends in the management of craniopharyngioma with a focus on endocrine outcomes.

Methods: This was a cross-sectional, multicentre study. Patients treated between 1951 and 2015 were identified and divided into four quartiles. Demographics, presentation, treatment and outcomes were collected.

Results: In total, 142 patients with childhood-onset craniopharyngioma (48/142; 34%) and adult-onset disease (94/142; 66%) were included. The median follow-up was 15 years (IQR 5-23 years). Across quartiles, there was a significant trend towards using transsphenoidal surgery ($P < .0001$). The overall use of radiotherapy was not different among the four quartiles ($P = .33$). At the latest clinical review, the incidence of GH, ACTH, gonadotrophin deficiencies and anterior panhypopituitarism fell significantly across the duration of the study. Anterior panhypopituitarism was not...
INTRODUCTION

Craniopharyngiomas are embryonic neoplasms of the sellar and parasellar region. With bimodal age distribution, craniopharyngiomas can manifest during childhood and adult life with pituitary and hypothalamic comorbidities from direct tumour infiltration and subsequent treatment.\(^1,2\) Pathologically, craniopharyngiomas are classified into two distinct variants; adamantinomatous subtype occurs mainly in paediatric patients and papillary subtype which is exclusive to adult population.\(^3\)

The location of the tumour in close approximation to vital intracranial structures and the risk of surgical damage to the hypothalamic-pituitary region have led to a growing trend towards more conservative surgery, aiming to preserve hypothalamic structures in particular, with a greater reliance on postoperative radiotherapy.\(^4-7\) It is not clear, however, whether this modern surgical approach is associated with improved long-term outcomes. Moreover, there is no consensus on the selection of patients for prophylactic radiotherapy or the optimal time to apply this treatment.\(^8\)

Recurrence is a common complication of craniopharyngiomas after initial therapy. Subsequent management of relapsed disease is often considered technically difficult with potentially increased morbidity and mortality.\(^9,10\)

In this multicentre clinical study, we investigated the management and outcomes of a large cohort of patients with craniopharyngioma from three tertiary endocrine centres in the United Kingdom. The primary aim of this study was to examine temporal trends in the management of craniopharyngioma and their impact on long-term patient’s endocrine function.

METHODS

In organizing this review of our clinical practice, we referred to the Health Research Authority online decision tool http://www.hra-decisiontools.org.uk/research/ which confirmed that Research approval was not required. This study was a multicentre cross-sectional study at three specialist pituitary services in London: Charing Cross Hospital, St Bartholomew’s Hospital and University College London Hospital. A search of electronic databases at each centre in 2015 identified all patients currently attending the clinic who were previously treated for craniopharyngioma. We performed a retrospective review of the case notes of all identified patients.

2.1 Data collection

Patients’ demographics, clinical presentation, treatment modalities and tumour regrowth were collected. In addition, details of patients’ outcomes including endocrine and metabolic outcomes were extracted. The cohort was divided into two groups, childhood-onset craniopharyngioma (COCP), defined as presentation before the age of 18 years, and adult-onset craniopharyngioma (AOCP), defined as presentation from 18 years of age onwards. Data related to tumour-directed treatment were collected about date and mode of surgery: transcranial (TCS) versus transsphenoidal surgery (TSS).

Prophylactic radiotherapy was defined as adjuvant radiotherapy administered after primary resection with the intention of preventing tumour regrowth, while therapeutic radiotherapy was defined as cranial irradiation administered for postoperative residual tumour postsurgery.

Tumour regrowth was defined as the need for further tumour-directed treatment (surgery or radiotherapy). Histopathological tumour subtype (adamantinomatous versus papillary) was recorded when available.

Persistent and late-developing complications including hypopituitarism, the presence of hyperlipidaemia and hyperglycaemia as well as anthropometric measurements were recorded as per the latest clinical review. The presence of hypertension, hyperlipidaemia and type two diabetes mellitus were defined when patients were prescribed antihypertensives, lipid-lowering agents and antidiabetic medications, respectively.
Pituitary hormone deficiencies were defined as follows: in the case of ACTH and TSH deficiency, patients were deficient if they were prescribed glucocorticoid and thyroxine replacement, respectively. Patients with diagnosis of primary hypothyroidism, recorded in the notes, were not included in the TSH deficient cohort. With respect to sex steroid deficiency, postmenopausal women with inappropriately normal or low serum gonadotrophins were gonadotrophin-deficient. Premenopausal women with amenorrhoea and nonelevated gonadotrophins were considered to be deficient in gonadotrophins. Men were gonadotrophin-deficient if they were prescribed testosterone replacement at last follow-up or if 9 AM serum testosterone concentration was low in the presence of inappropriately normal or low serum gonadotrophins. Patients with evidence of growth hormone (GH) deficiency on results of stimulation test or those currently treated with GH (peak serum GH < 3 μg/dL) were recorded as GH-deficient. In addition, patients with multiple pituitary hormone deficiencies defined as three or more deficiencies were considered to be deficient in GH. Anterior panhypopituitarism was considered when there was loss of three or more pituitary hormones. Patients were recorded as having cranial diabetes insipidus if they were prescribed maintenance desmopressin.

### Results

#### 2.2 Temporal trends

We divided the cohort into four consecutive groups. This was defined by the number of patients. Quartiles one and four contained 36 patients, while quartiles two and three contained 35 patients. Analysis of these equivalent size patient groups enabled meaningful evaluation of temporal trends in management, regrowth and complications. The first quartile contained the initial group of patients treated from the year 1951 onwards and the fourth quartile contained the most recently treated cases up to and including the year 2015. Dividing the cohort based on the date of surgery would result in unequal sized groups which are less amenable to statistical analysis.

### Statistical analysis

Basic data were evaluated using descriptive statistics. Median and interquartile range (IQR) were used to describe data not normally distributed. Chi-square test was used to compare categorical variables including the trend among investigator-defined treatment quartiles. Significance was defined as $P$-value < .05.

#### 3 RESULTS

#### 3.1 Patients' characteristics and initial clinical presentation

Data from 142 patients with COCP (48/142; 34%) and AOCP (94/142; 66%) were analysed in this study. The cohort was divided into 4 quartiles (Table 1). In COCP, the median age at diagnosis was 9 years (IQR 6–14 years). In AOCP, the median age at diagnosis was 36 years (IQR 25–51 years). Within COCP group, 30 patients were boys (30/48; 63%) and 18 were girls (18/48; 37%) with no gender predilection ($P = .16$). Within AOCP group, 49 patients were men (49/94; 52%) and 45 were women (45/94; 48%) with no gender predilection ($P = .76$). There was no gender difference between the two groups ($P = .28$).

Data on initial clinical presentation were available for variable number of patients. Visual disturbance was the presenting symptom in 84 patients of both age of onset groups (84/111; 76%) (including 17 patients presented with combined visual and hormonal disturbance), 21 COCP (21/29; 72%) and 63 AOCP (63/82; 77%). Thirty-five patients (35/109; 32%) presented with pituitary dysfunction (including 17 patients presented with combined visual and hormonal disturbance), 14 COCP (14/27; 52%) and 21 AOCP (21/82; 26%). Pituitary dysfunction was more common in COCP than AOCP ($P = .01$). Details of individual pituitary hormone deficiency at presentation with both onset of disease groups are as follows: GH deficiency occurred in 8 patients (8/11; 73%), and 12 patients (12/44; 27%) had secondary hypogonadism. Nine patients (9/34; 26%) had ACTH deficiency, and 11 patients (11/43; 26%) presented with secondary hypothyroidism.

### Table 1

| Quartile | COCP | AOCP |
|----------|------|------|
| Qtr1     | COCP | AOCP |
| Qtr2     | COCP | AOCP |
| Qtr3     | COCP | AOCP |
| Qtr4     | COCP | AOCP |

| Number | COCP | AOCP |
|--------|------|------|
| Qtr1   | 17 (47%) | 19 (53%) |
| Qtr2   | 17 (49%) | 18 (51%) |
| Qtr3   | 14 (40%) | 21 (60%) |
| Qtr4   | 0 (0%) | 36 (100%) |

| Surgery date | COCP | AOCP |
|--------------|------|------|
| Qtr1 | 1951-1990 | 1951-1990 |
| Qtr2 | 1990-1999 | 1990-1999 |
| Qtr3 | 1999-2008 | 1999-2008 |
| Qtr4 | 2009-2015 | 2009-2015 |

| TSS in the full cohort | COCP | AOCP |
|------------------------|------|------|
| Qtr1 | 7/25 (28%) | 9/36 (29%) |
| Qtr2 | 8/26 (31%) | 15/35 (43%) |
| Qtr3 | 16/35 (45%) | 35/36 (97%) |
| Qtr4 | 31/36 (86%) | 31/36 (86%) |

| TSS in COCP group | COCP | AOCP |
|-------------------|------|------|
| Qtr1 | (1/11; 9%) | (1/11; 9%) |
| Qtr2 | (3/13; 23%) | (3/13; 23%) |
| Qtr3 | (4/12; 33%) | (4/12; 33%) |
| Qtr4 | N/A | N/A |

| Radiotherapy | COCP | AOCP |
|--------------|------|------|
| Qtr1 | 20/35 (57%) | 26/35 (74%) |
| Qtr2 | 26/35 (74%) | 25/35 (71%) |
| Qtr3 | 25/35 (71%) | 15/35 (43%) |
| Qtr4 | 15/35 (43%) | 13/36 (36%) |

| Tumour regrowth | COCP | AOCP |
|----------------|------|------|
| Qtr1 | 8/36 (29%) | 15/35 (43%) |
| Qtr2 | 15/35 (43%) | 15/35 (43%) |
| Qtr3 | 15/35 (43%) | 13/36 (36%) |
| Qtr4 | N/A | N/A |
Eight patients (8/28; 29%) presented with anterior panhypopituitarism, and cranial diabetes insipidus occurred in 5 patients (5/47; 11%).

Headache was the presenting symptom in 11 patients of both age of onset groups (11/105; 9%), 6 COCP (6/23; 26%) and 5 AOCp (5/82; 6%). Headache was more common in the COCP group (P = .006).

### 3.2 Treatment

Details of technique for primary surgical excision were available for 125 patients, 36 COCP (36/125; 29%) and 89 AOCp (89/125; 71%). TSS was performed on 62 patients (62/125; 50%), 8 COCP (8/36; 22%) and 54 AOCp (54/89; 61%)—TSS was used more frequently in the AOCp group (P < .0001). TCS was performed on 63 patients (63/125; 50%) in the study group, 28 COCP (28/36; 78%) and 35 AOCp (35/89; 39%)—TCS was significantly more common in the COCP group (P < .0001). Cyst aspiration was performed on 14 patients, nine with COCP (9/36; 25%) and five with AOCp (5/89; 6%). Details of operating surgeons were available for 90 patients, 22 patients (22/71; 31%) in quartiles one and two and 68 patients (68/71; 96%) in quartiles three and four. Fifty patients underwent operations at the three participating centres by experienced neurosurgeons (MP, JG, ND, NM, DP, IA, GA and LA). Thirty-four patients underwent surgery in the UK outside the participating centres. Six patients had their operation overseas.

There was a significant trend across the study period towards using TSS for craniopharyngioma resection from 28% in quartile one to 86% in quartile four (P < .0001) (Table 1; Figure 1). However, the trend of using TSS was not significantly maintained when the COCP group was analysed separately (P = .163; Table 1).

Histological data were available for 47 AOCp (47/50; 94%). Thirty-six (36/47; 76%) had adamantinomatous craniopharyngioma, while 11 (11/47; 23%) had papillary craniopharyngioma. Histology reports were available for only three COCP all of whom were of the adamantinomatous subtype.

Data for radiotherapy were available for 138 patients. In total, 86 patients (86/138; 62%) received postoperative radiotherapy, 33 patients (33/86; 38%) and 53 patients (53/86; 62%) with COCP and AOCp, respectively, with no association with age of onset (P = .2). Fifty patients had radiotherapy type and dose recorded. Forty-nine patients (49/50; 98%) received conventional conformal radiotherapy, 4 patients received 25-45 Gray and 39 patients received 50-55 Gray. Sixty Gray was administered in one patient and five patients had no radiotherapy dose recorded. One patient (1/49; 2%) had gamma knife radiosurgery.

Prophylactic radiotherapy was given in 56 patients (56/86; 65%), and therapeutic radiotherapy was administered in 30 patients (30/86; 35%). The temporal trend of using radiotherapy across all four quartiles during the time course of the study was not significantly different (P = .33) (Table 1; Figure 2). There was no significant difference in the use of radiotherapy between those underwent TSS (32/62; 52%) and those had TCS (40/63; 63%; P = .17).

### 3.3 Tumour regrowth and outcome

The median follow-up was 15 years (IQR 5-23 years). In total, craniopharyngioma regrowth occurred in more than one-third of the patients (51/142; 36%) with median time of 3 years (IQR 1-6 years). There was no significant difference in tumour regrowth between COCP (16/48; 33%) and AOCp (35/94; 37%) (P = .4).

Among those treated with primary surgery and prophylactic radiotherapy (n = 56), 13 patients had regrowth (13/56; 23%); 12 patients needed further surgery and one patient was treated expectantly. Among those treated with surgery and no prophylactic radiotherapy (n = 86), 38 patients suffered craniopharyngioma regrowth (38/86; 44%), of which 24 patients (24/38; 63%) had further surgery and therapeutic radiotherapy, 7 patients (7/38; 18%) needed surgery, 6 patients (6/38; 16%) had therapeutic radiotherapy only, and one patient (1/38; 3%) was treated expectantly. Tumour regrowth was higher in patients treated with surgery only than those had
surgery and prophylactic radiotherapy ($P = .01$). Tumour regrowth was not associated with the histological type of craniopharyngioma in both age of onset groups ($P = 1.0$). There was no significant trend in craniopharyngioma regrowth across the four quartiles during the time course of the study ($P = .15$) (Table 1; Figure 3).

### 3.4 | Endocrine and metabolic characteristics at latest clinical follow-up

#### 3.4.1 | Hypopituitarism

Details of individual pituitary hormone deficiency, anterior panhypopituitarism and cranial diabetes insipidus at latest clinic follow-up are demonstrated in Table 2. The incidence of GH, gonadotrophins and ACTH deficiencies improved over the course of the study. Anterior panhypopituitarism was recorded in 113 patients (113/138; 82%) with no difference found between COCP (42/47; 89%) and AOC (71/91; 78%; $P = .1$). Anterior panhypopituitarism was similar in those treated with surgery only (43/55; 78%) compared to those who had surgery and radiotherapy (68/79; 86%) ($P = .23$) (Table S1). Anterior panhypopituitarism improved during the course of the study from 82% in quartile one to 63% in quartile four (Table 2) (Figure 4). Cranial diabetes insipidus occurred in 87 patients (87/139; 63%). There was no association in cranial diabetes insipidus between COCP (32/47; 67%) and AOC (55/92; 60%) ($P = .29$), and no significant difference was observed among all quartiles ($P = .27$) (Table 2).

#### 3.4.2 | Metabolic parameters

BMI data were available for 105 patients of COCP and AOC. Overall, 88 patients (88/105; 84%) had raised BMI over 25 kg/m$^2$, 35 patients (35/44; 80%) had COCP, and 53 patients (53/61; 86%) had AOC with no significant difference in prevalence of obesity between the two groups ($P = .31$). The median BMI was 29.2 kg/m$^2$ (IQR 25.5-34.6 kg/m$^2$). Only 17 patients (17/105; 16%) of both age of onset groups maintained normal weight (BMI 18.5 and 24.9 kg/m$^2$); more than one-third (37/105; 35%) were overweight (BMI 25 to 29.9 kg/m$^2$), and approximately a quarter of patients had class 1 obesity (BMI 30.0 to 34.9 kg/m$^2$) (27/105; 26%), whereas class II (BMI 35.0 to 39.9 kg/m$^2$) and class III obesity (BMI equal to or greater than 40.0 kg/m$^2$) were less prevalent in this cohort (11/105; 11% and 13/105; 12%), respectively. High BMI ($\geq$25 kg/m$^2$) was not associated with the mode of surgery (TSS vs TCS) ($P = .5$) and the age group at onset ($P = .31$). Higher BMI ($\geq$25 kg/m$^2$) was noted in those received radiotherapy (61/67; 91%) than those treated with surgery only (26/37; 70%) ($P = .006$). The median BMI for those received postoperative radiotherapy was 30.6 kg/m$^2$ and for those treated with surgery only was 25.9 kg/m$^2$. There was no significant difference in the incidence of raised BMI ($\geq$25 kg/m$^2$) among all quartiles during the time course of the study ($P = .4$; Table 2).

Data for hyperlipidaemia and hypertension were available for 136 patients. Thirty-three patients of both age groups at onset (33/136; 24%) were prescribed lipid-lowering agents, 8 COCP (8/47; 17%) and 25 AOC (25/89; 28%) with no significant difference between the two groups ($P = .15$). The temporal trend for the use of lipid-lowering agents was not significant across the four quartiles ($P = .41$). Twenty-three patients of COCP and AOC (23/136; 17%) were receiving antihypertensives, 5 COCP (5/47; 11%) and 18 AOC (18/89; 20%) with no significant difference between the two groups ($P = .16$). The trend of antihypertensive therapy over the course of the study was not significant ($P = .15$). Data for antidiabetic therapy were available for 134 patients, 19 patients (19/134; 14%) from both age of onset groups required antidiabetic therapy, 3 COCP (3/48; 6%) and 16 AOC (16/86; 18%). The incidence of type two diabetes mellitus was associated with age of onset ($P = .04$), but the overall incidence of type two diabetes mellitus among quartiles did not differ ($P = .67$).

### 4 | DISCUSSION

In this large UK multicentre study of craniopharyngioma, with a long duration of follow-up, we have demonstrated a significant temporal trend in favour of less long-term hypopituitarism. This suggests that modern management techniques of both COCP and AOC are associated with greater preservation of pituitary hormone reserve. At last clinical review, anterior panhypopituitarism affected 82%, while 63% suffered cranial diabetes insipidus. This is in line with other reported data reporting the endocrine impact of craniopharyngioma. Wijnen et al reported higher frequency of secondary hypogonadism at 92% in 128 patients after a median follow-up of 13 years. In addition, they observed a higher rate of anterior panhypopituitarism and cranial diabetes insipidus in COCP than AOC. Lo AC et al observed lower rate of GH and gonadotrophin deficiency in 123 patients at 47% and 55%, respectively, during a median follow-up of 8.9 years. However, these studies did not analyse the temporal trend in patient outcomes as well as refinements in endocrine...
TABLE 2 The incidence of individual pituitary hormone deficiency, anterior panhypopituitarism, cranial diabetes insipidus and BMI (≥25 kg/m²) of the full cohort at latest clinical follow-up across all four quartiles

|            | Total number | Qtr1 | Qtr2 | Qtr3 | Qtr4 | P-value |
|------------|--------------|------|------|------|------|---------|
| GH         | 119/135 (88%)| 34/35 (97%)| 31/34 (91%)| 31/33 (94%)| 23/33 (70%)| .001    |
| FSH/LH     | 99/121 (81%) | 28/30 (93%)| 25/30 (83%)| 24/29 (83%)| 22/33 (67%)| .01     |
| ACTH       | 116/141 (82%)| 31/35 (89%)| 30/35 (86%)| 31/35 (88%)| 24/36 (67%)| .03     |
| TSH        | 119/139 (86%)| 31/35 (89%)| 31/35 (89%)| 32/36 (89%)| 25/34 (74%)| .1      |
| APH        | 113/138 (82%)| 31/35 (88%)| 30/34 (88%)| 31/34 (91%)| 21/35 (63%)| .004    |
| Cranial DI | 87/139 (63%) | 22/35 (63%)| 27/33 (82%)| 19/35 (54%)| 20/35 (57%)| .3      |
| BMI (≥25 kg/m²) | 88/105 (84%) | 19/26 (73%)| 27/31 (87%)| 24/28 (85%)| 18/20 (90%)| .14     |

Abbreviations: ACTH, adrenocorticotropic hormone; APH, anterior panhypopituitarism; BMI, body mass index; DI, diabetes insipidus; FSH, follicle-stimulating hormone; GH, growth hormone; LH, luteinizing hormone; Qtr, quartile; TSH, thyroid-stimulating hormone.

FIGURE 4 The trend of anterior panhypopituitarism at latest clinical review in the full cohort. The dark bars represent patients with panhypopituitarism, while grey bars represent those with no panhypopituitarism. Qtr, quartile

Care over a prolonged period. We did not detect a significant difference in anterior panhypopituitarism between those who underwent surgery only and those treated with combined surgery and radiotherapy. Length of follow-up postradiotherapy for quartile four ranged between 1 and 5 years. Notably, this was significantly shorter than for other quartiles and this may have contributed to the lower observed rates of hypopituitarism. A previous study of pituitary tumour patients receiving radiotherapy with follow-up for up to ten years reported that most GH and gonadotrophin deficiency occurred within five years following radiotherapy. There was a lower incidence of GH and gonadotrophin deficiency in quartile four (Table 2); this may represent a trend towards less hypopituitarism.

Radiotherapy and radiosurgery are increasingly relied upon to prevent and treat tumour recurrence and regrowth in craniopharyngioma. More than two-thirds of patients in this cohort received radiotherapy to provide tumour control which is comparable with other studies. Timing of cranial irradiation post-surgery remains controversial. There may be reluctance to offer immediate postoperative radiotherapy because of the potential risk of long-term neurovascular consequences and secondary malignancy especially in children and young adults. However, others support the administration of early radiotherapy to control tumour progression after resection to avoid further surgical intervention. Several studies demonstrated no significant difference in progression-free survival after early postoperative versus late radiotherapy for tumour regrowth. In contrast, others found fewer craniopharyngioma relapse with early radiotherapy given as initial therapy when compared with those received late radiotherapy for recurrence. In our series, prophylactic radiotherapy was delivered in 65% of those received radiotherapy. Significant number of patients in this group suffered tumour regrowth. However, tumour regrowth was lower in those had surgery plus prophylactic radiotherapy than those treated with surgery only. Other studies reported this outcome involved smaller number of patients with shorter follow-up duration when compared to this series. The temporal trend in the use of radiotherapy was not different across the quartiles when compared to surgical technique. The administration of radiotherapy was not influenced by the route of surgery (TSS vs TCS). One of the important limitations here is the lack of detailed data of preoperative tumour size and immediate postsurgical tumour volume reduction which may be an important influencing factor. These data were not consistently available for this cohort and were therefore not included in the analysis.

Direct hypothalamic invasion or damage secondary to surgery/radiotherapy is associated with adverse metabolic and cardiovascular morbidities. Disruption of the regulatory centres in the hypothalamus alters physical tolerance, bodily energy consumption and satiety. Consequently, craniopharyngioma patients may develop hypothalamic obesity and metabolic syndrome. Excess weight is prevalent in up to 19% in COCP at presentation, with higher obesity rates of 30%-55% after successful therapy despite adequate hormone replacement. In our series, obesity (BMI ≥ 30 kg/m²) occurred in 49% of those who had BMI data available which is in agreement with other studies. Those who received radiotherapy had a higher BMI than those treated with surgery only. This might be attributed to the possibility of presentation with larger, more invasive tumours in this group prior to radiotherapy. Lustig et al noted hypothalamic irradiation of greater than 51 Gy was an independent
risk factor for developing obesity in children who had received cranial irradiation for different brain tumours, and this effect was observed even after excluding patients with hypothalamic/thalamic tumours.

Patients with pituitary dysfunction have higher rates of cardiovascular complications and premature mortality when compared to the general population. A high prevalence of hyperlipidaemia, hypertension and insulin resistance are possible contributors. In this cohort, we identified the diagnoses of dyslipidaemia, hypertension and type two diabetes mellitus by therapy. However, we acknowledge that there may be differences in thresholds in treating cardiovascular risk factors in pituitary patients in different settings, with no clear evidence-based guidance. Consequently, patients defined as having increased cardiovascular risk might differ across centres and quartiles and indeed the results from our cohort are likely to under-represent the true occurrence of these risk factors in such patients. In addition, the lack of detailed hormones deficiencies data at presentation for most of the patients might bias metabolic outcomes in this cohort.

Since this study relied on recruiting patients at latest clinical review, this possibly introduced a selection bias caused by an uncertain number of patients who had been lost to follow-up or died. This may have particularly affected the quartiles treated at early stages of the study period and therefore this could potentially have introduced some bias. Defining hormone deficiency based on replacement therapy is of course less robust than analysing endocrine results prior to replacement; however, the nature of the study, with such a long follow-up across multiple centres/laboratories, would have made this very difficult.

The data extraction was based on retrospective review of medical records and hence is subjective to inherent limitations of retrospective studies. Other limitations include the lack of complete data of preoperative tumour size and the extent of surgical excision. The potential bias of different follow-up duration across quartiles should be taken into consideration. Statistical analysis used to calculate the trend in all four quartiles was invariably significantly influenced by the change from quartile three to quartile four. In addition, the histological data in this series are limited which precludes meaningful conclusion of cranioophangiroma regrowth. However, our study included a large number of cranioophangiroma patients with childhood and adult onset, despite the rarity of the condition, with long median follow-up duration. It highlights the extent of long-term endocrine complications in cranioophangiroma particularly obesity rate, hypertension and type two diabetes mellitus.

In conclusion, cranioophangiroma is associated with substantial endocrine-related morbidities. The incidence of panhypopituitarism reduced significantly with the advent of new surgical techniques, notably TSS. The role of immediate radiotherapy postresection remains controversial. Cranioophangiroma survivors require lifelong follow-up and mandate multidisciplinary expertise to optimize overall outcome.

ACKNOWLEDGEMENTS
The authors would like to thank Dr Raquel Sanchez Windt, visiting clinical fellow, Department of Endocrinology, St Bartholomew’s Hospital, Bart’s Health NHS Trust, London, UK, for help with data collection.

CONFLICT OF INTEREST
All authors have completed conflict of interest statement. https://onlinelibrary.wiley.com/page/journal/13652265/homepage/forauthors.html#preparing. Hani J Marcus is supported by the Wellcome/ EPSRC Centre for Interventional and Surgical Sciences (WEISS) and the NIHR BRC Neuro-oncology.

DATA AVAILABILITY STATEMENT
The data that supports the findings of this study are openly available at https://doi.org/10.5522/04/12023025.v1

REFERENCES
1. Karavitaki N, Brufani C, Warner JT, et al. Cranioophangiromas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf). 2005;62(4):397-409.
2. Steinbok P. Cranioophangiroma in children: long-term outcomes. Neurul Med Chir (Tokyo). 2015;55(9):722-726.
3. Lubuulwa J, Lei T. Pathological and topographical classification of cranioophangiromas: a literature review. J Neurol Surg Rep. 2016;77(03):e121-e127. https://doi.org/10.1055/s-0036-1588060
4. Sughrue ME, Yang I, Kane AJ, et al. Endocrinologic, neurologic, and visual morbidity after treatment for cranioophangiroma. J Neurooncol. 2011;101(3):463-476.
5. Lin LL, El Naqa I, Michalski JM, et al. Long-term outcome in children treated for cranioophangioma with and without radiotherapy. J Neurosurg Pediatr. 2008;12(2):126-130.
6. Yang I, Sughrue ME, Rutkowski MJ, et al. Cranioophangiroma: a comparison of tumor control with various treatment strategies. Neurosurg Focus. 2010;28(4):1-11.
7. Marcus HJ, Rasul FT, Hussein Z, et al. Cranioophangiroma in children: trends from a third consecutive single-center cohort study. J Neurosurg Pediatr. 2020;25(3):242-250.
8. Kortmann R-D. Different approaches in radiation therapy of cranioophangioma. Front Endocrinol (Lausanne). 2011;2:100.
9. Caldarelli M, Di Rocco C, Papacci F, Colosimo C. Management of recurrent cranioophangioma. J Clin Neurosci. 18, 451-457.
10. Minamida Y, Mikami T, Hashi K, Houkin K. Surgical management of the recurrence and regrowth of cranioophangiromas. J Neurosurg. 2005;103(2):224-232.
11. Shalet SM, Toogood A, Rahim A, Brennan BMD. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev. 1998;19(2):203-223.
12. Wijnen M, van den Heuvel-Eibrink MM, Janssen JAMJL, et al. Very long-term sequelae of cranioophangiroma. Eur J Endocrinol. 2017;176(6):755-767.
13. Karavitaki N, Cudlip S, Adams CBT, Wass JAH. Cranioophangiromas. Endocr Rev. 2006;27(4):371-397.
14. Lo AC, Howard AF, Nichol A, et al. Long-term outcomes and complications in patients with craniopharyngioma: The British Columbia cancer agency experience. *Int J Radiat Oncol Biol Phys*. 2014;88(5):1011-1018.

15. Müller HL. Craniopharyngioma. *Endocr Rev*. 2014;35(3):513-543.

16. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. *QJM*. 1989;70(2):145-160.

17. Stripp DCH, Maity A, Janss AJ, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. *Int J Radiat Oncol Biol Phys*. 2004;58(3):714-720.

18. Moon SH, Kim IH, Park SW, et al. Early adjuvant radiotherapy toward long-term survival and better quality of life for craniopharyngiomas—a study in single institute. *Child’s Nerv Syst*. 2005;21(8-9):799-807.

19. Regine WF, Mohiuddin M, Kramer S. Long-term results of pediatric and adult craniopharyngiomas treated with combined surgery and radiation. *Radiother Oncol*. 1993;27(1):13-21.

20. Lin LL, El Naqa I, Leonard JR, et al. Long-term outcome in children treated for craniopharyngioma with and without radiotherapy. *J Neurosurg Pediatr*. 2008;1(2):126-130.

21. Weiss M, Sutton L, Marcial V, et al. The role of radiation therapy in the management of childhood craniopharyngioma. *Int J Radiat Oncol Biol Phys*. 1989;17(6):1313-1321.

22. Merchant TE, Kiehna EN, Sanford RA, et al. Craniopharyngioma: the St. Jude Children’s Research Hospital experience 1984–2001. *Int J Radiation Oncol Biol Phys*. 2002;53(3):533-542.

23. Müller H. L. Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity. *Curr Opin Endocrinol Diabetes Obes*. 2016;23(1):81-89.

24. Roth C. Hypothalamic obesity in craniopharyngioma patients: disturbed homeostasis related to extent of hypothalamic damage and its implication for obesity intervention. *J Clin Med*. 2015;4(9):1774-1797.

25. Müller HL. Consequences of craniopharyngioma surgery in children. *J Clin Endocrinol Metab*. 2011;96(7):1981-1991.

26. Lustig RH, Post SR, Srivannaboon K, et al. Risk factors for the development of obesity in children surviving brain tumors. *J Clin Endocrinol Metab*. 2003;88(2):611-616.

27. Bülow B, Hagmar L, Eskilsson J, Erfurth EM. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors 1. *J Clin Endocrinol Metab*. 2000;85(2):574-584.

28. Rosén T, Bengtsson BÅ. Premature mortality due to cardiovascular disease in hypopituitarism. *Lancet*. 1990;336(8710):285-288.

29. Deepak D, Furlong NJ, Wilding JPH, MacFarlane IA. Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. *Postgrad Med J*. 2007;83(978):277-280.